BioSpace News Archive

Agility at work. This professional buzzword is one of the most popular, highly valued workplace concepts today. Learn more about it this important concept here.

Getting noticed in your workplace sometimes requires more than simply completing your tasks or meeting your goals. In order to be a true stand-out at work and position yourself as an integral player in your organization, the unique value that you bring on a daily basis needs to be communicated in a variety of ways over time, some professional and some personal.

Do you find it difficult to make time to go to the gym or keep up with a regular exercise program outside of work? If your work schedule doesn’t permit spending hours at the gym or exercising every week, you should do your best to find creative ways to incorporate physical activity into your workday.

How can you tell when enthusiasm, ambition, or committment for your job turns into an unhealthy obsession or addiction? Being addicted to your job can become just as crippling and disruptive as any other addiction, obsession, or compulsion.

Can’t figure out why you’re not more successful in your career or advancing up the professional ladder more quickly? Maybe you should sleep on it… literally.

Pfizer reported its second-quarter financials, with adjusted earnings per share coming in at $0.81, exceeding the consensus forecast of $0.74, up 20.9 percent from the same period in 2017.

The U.S. Food and Drug Administration (FDA) approved New York-based Progenics Pharmaceuticals’ New Drug Application (NDA) for Azedra for adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy. It is the first and only therapy approved for these indications.

For its second-quarter financial report, Paris-based Sanofi reported a decrease in net sales for the quarter of 5.7 percent, down to 8.176 billion euros. Sanofi’s diabetes and cardiovascular franchises have struggled in the U.S.

Astex Pharmaceuticals, a member of the Otsuka group of companies, and Otsuka Pharmaceutical, indicated their guadecitabine (SGI-110) missed its co-primary endpoints in acute myeloid leukemia (AML).

In March, San Diego-based Orexigen Therapeutics filed for bankruptcy. Back in April, Orexigen entered into an asset purchase deal with Nalpropion Pharmaceuticals to sell most of its assets, subject to court approval.